ELISpot and FluoroSpot Assay Market To Generate $490.8 Million Revenue by 2030

The ELISpot and FluoroSpot assay market size is expected to advance at a CAGR of 7.9% during 2024–2030, to reach USD 490.8 million by 2030. This is primarily because of the rise in the geriatric people, which spurs the prevalence of infectious diseases. Further, in developing countries, the rise in the prevalence of chronic non-communicable diseases, such as heart diseases, cancer, and diabetes, reflect changes in the lifestyle and diet, as well as aging.

It is further expected developing regions will be home to almost 8 out of 10 of the world’s older persons by 2050. Moreover, the number of persons aged 60 years or over in developing regions is expected to increase from 652 million in 2017 to 1.7 billion by 2050.

The world’s deadliest infections are HIV/AIDS, malaria, and tuberculosis. They have been considered the big three infectious diseases (BTIDs) with the most deaths every year. In 2022, TB is the second-largest infectious killer after COVID-19. In 2021, 10.6 million people in all age groups across all countries fell ill with TB globally.

Similarly, in 2021, there were 247 million cases of malaria worldwide. Malaria is caused by a parasite, which enters humans’ bloodstream when infected mosquitoes bite.

The ELISpot assay is also used in the detection of COVID-19 antibodies. In a study, it was found that 78% of the antibodies detected by ELISpot are not detected by PCR-positive volunteers. Thus, the ongoing COVID-19 pandemic has been a major driver for the ELISpot and FluoroSpot assay market.

Wide Usage of ELISpot Assays during Research on Vaccines

The ELISpot assay is commonly used in research to measure the immune response in humans and mice, because it is highly quantitative and can precisely measure the magnitude of the response. ELISpot's transformation from a research tool to a clinical assay, therefore, makes sense. ELISpot may be a helpful biomarker assay to forecast clinical benefit following therapeutic immune modulation, according to recent Phase I and II studies of vaccines for a range of malignancies. ELISpot is now the most-widely used immunoassay in the evaluation of the clinical trials of vaccines and other forms of immunotherapy.

Growing Demand for ELISpot and FluoroSpot Analyzers

Analyzer held a 20% share in 2023. In 1995, Cellular Technology Limited (CTL) developed image analysis-based ELISPOT counting, which was considered the genesis of ImmunoSpot analyzers.

ImmunoSpot is capable of conducting tests that are widely used in immune response monitoring, such as cytotoxicity, PMBC counting, and cytokine array reading. The analyzer combines many tools available for the price of one, thus savings costs for users. Some of the analyzers available are S6 FluoroCore M2, S6 Ultra M2, S6 Flex M2, S6 Universal M2, and S6 Ultimate M2.

Asia-Pacific Is Fastest-Growing Region

The Asia-Pacific market is projected to grow the fastest during the forecast period. China is expected to hold the largest share of the ELISpot and FluoroSpot market in the region. This is due to the rise in the number of assay kit producers, increase in research and innovation activities, and surge in the investments in healthcare facilities.

Similarly, in the European region, Germany is expected to be the fastest-growing market for ELISpot and FluoroSpot products. The advancement in research as a result of the partnerships between life sciences companies and research universities is driving the market growth.

Some of the key players in the ELISpot and Fluorospot market are OXFORD IMMUNOTEC, Cellular Technology Limited, Mabtech AB, Becton, Dickinson and Company, and Bio-Techne Corporation.